Publications by authors named "K Delavigne"
Article Synopsis
- Immunological checkpoint inhibitors, used in treating various cancers, can cause toxic side effects, particularly dermatological disorders.
- Common skin issues like maculopapular erythema and pruritus often occur, but rarer conditions such as fasciitis and scleroderma can also arise.
- Recognizing these unusual manifestations is crucial for internists, as they may mimic other diseases or paraneoplastic syndromes, requiring specific diagnostic and treatment approaches related to ICI toxicity.
Article Synopsis
- - Immune checkpoint inhibitors (ICIs) like nivolumab can lead to rare immune-related adverse events, including acquired amegakaryocytic thrombocytopenia (AAT), which is characterized by low platelet counts and absence of megakaryocytes in the bone marrow.
- - A case study of a patient with metastatic melanoma showed that after 12 cycles of nivolumab, he developed AAT, but responded positively to eltrombopag, an oral drug known to increase platelet production.
- - Despite similar cases reported in literature, there’s uncertainty in treatment guidelines for immune-related AAT; ongoing research is needed to establish safety measures for therapies such as thrombopoietin receptor agonists in cancer patients.
Rationale: The use of autologous hematopoietic stem cell transplantation (AHSCT) for autoimmune diseases has become the first indication for transplant in nonmalignant disease. Mucormycosis is a rare invasive infection with increasing incidence in patients treated with AHSCT. We report the first case of pulmonary mucormycosis following AHSCT for systemic sclerosis (SSc).
View Article and Find Full Text PDFDifferent dosage regimens of hydroxychloroquine are used to manage coronavirus disease 2019 (COVID-19) patients, without information on the pharmacokinetics in this population. Blood samples (n = 101) were collected from 57 COVID-19 patients for 7 days, and concentrations were compared with simulated kinetic profiles. Hydroxychloroquine exposure is low and cannot be predicted by other populations.
View Article and Find Full Text PDFMyelodysplastic syndromes are a heterogeneous group of clonal myeloid disorders characterized by peripheral cytopenias and an increased risk of progression to acute myeloid leukemia. Inflammatory, auto-immune or syndromic symptoms can make the diagnosis difficult. Diagnosis is currently based on bone marrow cytology but cytogenetics and molecular features are currently overpassing their initial prognostic function (allowing early diagnosis and prediction of therapeutic response).
View Article and Find Full Text PDF